Predictive risk factors for relapse after cessation of inhaled corticosteroids in well-controlled childhood XXXX .

@entity1 @entity225 @entity697 @entity4047 @entity565 @entity2490 @entity1503 @entity688 @entity16179 @entity379 @entity230 @entity6587 @entity2710
AIM: There is limited data for predicting the risk of exacerbations following the cessation of inhaled @entity230 ( @entity16179 ) in well controlled childhood @entity565 . In current study, clinical, functional and inflammatory parameters at the time of @entity16179 withdrawal were investigated in that respect. METHODS: Forty @entity1 asymptomatic for at least 3 months on low dose @entity16179 's were enrolled and @entity16179 were discontinued in summer. At enrolment symptom/medication diary, pulmonary function parameters, @entity2710 provocation testing, peripheral @entity1503 , serum total and allergen-specific IgE levels and skin prick testing were performed. In a subgroup of @entity1 , phytohemaglutinin induced secretion of @entity225 , @entity4047 , @entity379 and @entity688 from blood mononuclear cells were measured. @entity1 were assessed with symptom/medication diary and pulmonary function test every 2 months for 6 months. RESULTS: Eighteen of 37 @entity1 experienced recurrence of @entity697 . In @entity1 with acute attack(Group I), changes in @entity2490 symptom scores at 2nd month vs baseline were statistically higher. In addition, group I had significantly higher @entity2490 symptom scores compared to group II at 4th month visit. @entity1 with acute exacerbation revealed a significant decrease in FEV1% at 2nd month compared to baseline. Moreover, group I showed significantly lower FEF 25-75% compared to group II at 2nd month. Baseline bronchial hyper-responsiveness with @entity2710 was found to be an independent risk factor for @entity565 exacerbation. CONCLUSION: The findings of this study identified baseline @entity6587 , higher @entity2490 symptom scores and gradual decrease in pulmonary function parameters during follow up as risk factors for subsequent exacerbation of @entity565 .
